Maria Cervantes Fullmer
Hematology & Oncology · Idaho Falls, IDNPI 1477020303
Payments from drug & device makers
Across 466 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$853
- AstraZeneca$820
- Lilly USA, LLC$758
- Novartis$553
- Daiichi Sankyo Inc.$517
- Johnson & Johnson$453
- plus $5K from 48 others
What the payments were for
- Food & beverage$7,86386%
- Education$1,29914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$9,162 in reported general payments places this provider in the 50th percentile of 34 hematology & oncology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 16 | $276,951 |
| TagrissoOsimertinib Mesylate | 12 | $199,345 |
| KisqaliRibociclib Succinate | 11 | $149,034 |
| EliquisApixaban | 76 | $50,142 |
| Ondansetron Hcl | 43 | $26,229 |
| XareltoRivaroxaban | 16 | $10,818 |
| Fentanyl | 26 | $4,798 |
| Exemestane | 11 | $4,090 |
| ValacyclovirValacyclovir Hcl | 48 | $1,745 |
| Letrozole | 74 | $1,488 |
| Potassium Chloride | 60 | $1,264 |
| Ondansetron OdtOndansetron | 29 | $1,199 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $675 |
| Dexamethasone | 21 | $627 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 31 | $444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $191 | $276,95116 claims |
| AstraZenecaTagrisso | $820 | $199,34512 claims |
| NovartisKisqali | $553 | $149,03411 claims |
| PfizerEliquis | $853 | $50,14276 claims |
| Johnson & JohnsonXarelto | $453 | $10,81816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 34 hematology & oncology providers in Idaho.
Other hematology & oncology in Idaho Falls
- Christian ShullIdaho Falls$150K
- Nathan AdamsIdaho Falls$16K
- Danko MartincicPost Falls$3.5M
- Bobby ChawlaCaldwell$1.1M
- Kerry PulverBoise$778K
- Dan ZuckermanBoise$537K
- William KreisleBoise$296K
- Ian QureshiNampa$49K
- Shane AhlersBoise$46K
- Olga DermanBoise$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.